Pictet Asset Management Holding SA grew its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 10.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 119,489 shares of the company’s stock after buying an additional 11,691 shares during the quarter. Pictet Asset Management Holding SA owned about 0.40% of Krystal Biotech worth $39,737,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently made changes to their positions in KRYS. Hsbc Holdings PLC acquired a new position in shares of Krystal Biotech during the second quarter valued at approximately $3,653,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Krystal Biotech in the second quarter worth approximately $3,865,000. Congress Asset Management Co. lifted its position in Krystal Biotech by 34.8% in the third quarter. Congress Asset Management Co. now owns 54,083 shares of the company’s stock worth $17,986,000 after purchasing an additional 13,949 shares during the period. Corient Private Wealth LP boosted its stake in Krystal Biotech by 767.4% during the second quarter. Corient Private Wealth LP now owns 30,558 shares of the company’s stock valued at $11,357,000 after buying an additional 27,035 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Krystal Biotech by 36.6% in the 1st quarter. Bank of America Corp DE now owns 260,647 shares of the company’s stock worth $67,330,000 after purchasing an additional 69,840 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino Rossi sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at approximately $16,456,000. This represents a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 13.10% of the company’s stock.
Krystal Biotech Trading Up 1.1%
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its earnings results on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.26. The company had revenue of $127.34 million for the quarter, compared to analysts’ expectations of $125.77 million. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. On average, equities analysts forecast that Krystal Biotech, Inc. will post 7.74 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on the stock. Royal Bank Of Canada decreased their price target on shares of Krystal Biotech from $400.00 to $375.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 3rd. Zacks Research downgraded shares of Krystal Biotech from a “hold” rating to a “strong sell” rating in a research report on Friday, October 23rd. Bank of America raised their price objective on shares of Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. HC Wainwright reiterated a “buy” rating and set a $361.00 price objective on shares of Krystal Biotech in a research report on Thursday, October 15th. Finally, William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Wednesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of “Moderate Buy” and an average price target of $375.00.
View Our Latest Stock Analysis on Krystal Biotech
Krystal Biotech Company Profile
Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.
See Also
- Five stocks we like better than Krystal Biotech
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
